Profile of Remimazolam in Anesthesiology: A Narrative Review of Clinical Research Progress
Mi Wang,Xian Zhao,Pengfei Yin,Xiuxia Bao,Hongli Tang,Xianhui Kang
DOI: https://doi.org/10.2147/DDDT.S375957
2022-10-04
Abstract:Mi Wang, 1, &ast Xian Zhao, 2, &ast Pengfei Yin, 1 Xiuxia Bao, 1 Hongli Tang, 3 Xianhui Kang 1 1 Department of Anesthesiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China; 2 Department of Anesthesiology, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, People's Republic of China; 3 Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xianhui Kang, Department of Anesthesiology, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, Zhejiang, People's Republic of China, Tel +86-0571-87236169, Fax +86-21-57643271, Email Hongli Tang, Department of Anaesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China, Tel +86-577-87236169, Fax +86-21-57643371, Email Remimazolam is a novel short-acting γ-aminobutyric acid (GABA) receptor agonist with typical characteristics of benzodiazepine sedative drugs, nonorgan-dependent metabolism, long-term infusion without accumulation, and no injection pain. It is quite different from the other current sedative drugs and has broad prospects for application. It has been established that the metabolites of remimazolam are inactive, and the interactions with other drugs are weak with slight cardiopulmonary suppressive effects, showing good effectiveness and safety. During the 2-year period that it has been on the market, remimazolam has been used in multiple clinical scenarios, such as the induction and maintenance of general anesthesia and sedation in outpatient minor procedures or examinations. However, it's use has also prompted widespread concern around the world. Therefore, given its short- and rapid-acting, controllable characteristics remimazolam deserves in-depth study in order for it to be used in fast-track surgery, comfort diagnosis and treatment. Notably, such agents might be of great significance, especially in elderly individuals, patients with critical diseases or patients with liver and kidney insufficiency. The current study reviews recent clinical studies (2015– 2022) on remimazolam and summarizes the characteristics of its applications. Specifically, the use of remimazolam in some specific populations are described. This study attempts to provide scientific support for the clinical application of this novel sedative drug in the field of anesthesia. Keywords: remimazolam, anesthesia, sedation, benzodiazepine, clinical Remimazolam is a novel ester-benzodiazepine sedative drug that has been approved for use in the clinic since 2020. It is derived from midazolam and synthesized via the introduction of a methyl-propionate side chain of metabolic potential. 1 Therefore, remimazolam combines the properties of midazolam and remifentanil. It belongs to class 1.1 of new drugs with two major salt forms: benzene sulfonic acid and toluenesulfonic acid. 2 With the promotion of fast-track surgery, increasing attention has been given to optimizing perioperative medication, advancing the early recovery of organ function and decreasing the incidence of adverse events. 3 Remimazolam has multiple advantages, such as a slight circulatory suppressive effect and liver and kidney function-independent metabolism. 4 During the 2-years it has been on the market, remimazolam has prompted widespread concern and has emerged as an ideal sedative drug for populations at an advanced age or in a vulnerable state. In addition, it possesses unique advantages in outpatient endoscopy and treatment, procedures, and regional blockade with adjuvant sedation, owing to its being rapid- and short-acting, slight respiratory suppressive effects and the absence of injection pain. Preliminary clinical studies have also been conducted in some specific surgeries, such as cardiopulmonary bypass surgery and neurosurgery requiring intraoperative awakening. Given the advantages mentioned above, remimazolam, as a new sedative drug, is mainly used in endoscopic examination and treatment, induction and maintenance of general anesthesia and sedation in intensive care unit (ICU) patients. However, the pharmacological characteristics and application scenarios of remimazolam in the clinic remain to be fully clarified due to the short time it has been on the market and limited clinical trials with a small sample size. In this review, we describe the progress of the clinical application of remimazolam, introduce its methods and advantages, and finally, briefly, discuss the -Abstract Truncated-